The Week in Weed: February 27, 2026 – Lexology

? As cannabis legalization continues to expand across jurisdictions, clinicians should recognize that regulatory frameworks and legal status remain in flux, which complicates patient counseling and medical documentation. The fragmented landscape of state and federal policy creates uncertainty around product standardization, quality assurance, and long-term liability considerations that directly affect clinical decision-making regarding cannabis recommendations or co-management with other medications. Healthcare providers must stay informed about evolving legal definitions of medical versus recreational cannabis, as these distinctions influence insurance coverage, workplace drug testing policies, and potential occupational consequences for patients. While regulatory changes may eventually improve product transparency and dosing consistency, current variability means clinicians should document cannabis use thoroughly, screen for drug interactions carefully, and counsel patients on the persistent legal risks in their jurisdiction. A practical approach involves maintaining updated knowledge of local regulations and adopting a harm-reduction stance that acknowledges both cannabis’s potential therapeutic applications and the regulatory uncertainty that currently limits robust clinical